GlassScriptPhysician profile
Michael Jay Boling
NPI 1124295134
$3,905.52
in general payments reported to CMS, 2019-2025
35 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.44 · 2021: $411 · 2022: $773 · 2023: $874 · 2024: $524 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $622.60 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $432.17 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $379.07 | 2021-2024 | Arexvy, Bexsero, Trelegy Ellipta |
| Astellas Pharma US INC | $259.18 | 2023-2025 | Veozah |
| Novo Nordisk INC | $254.01 | 2022-2025 | Wegovy, Saxenda, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.33 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $200.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $161.34 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $154.97 | 2021-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Abiomed | $154.03 | 2023 | Impella |
| Sanofi-Aventis U.S. LLC | $123.41 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $120.25 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $81.97 | 2021-2022 | |
| Corcept Therapeutics | $78.44 | 2023-2025 | Korlym |
| Abbvie INC. | $69.04 | 2023-2025 | Mavyret, Viberzi, Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $68.07 | 2021-2022 | |
| Hologic Sales and Service, LLC | $50.30 | 2022 | |
| Pfizer INC. | $44.32 | 2023-2025 | |
| Abbott Laboratories | $41.82 | 2024-2025 | Freestyle Libre 3, Diamondback Coronary |
| Phathom Pharmaceuticals, INC. | $41.35 | 2024 | Voquezna |
| Insulet Corporation | $34.95 | 2025 | Omnipod |
| Phadia US INC. | $34.11 | 2021-2025 | Immunocap |
| Ultragenyx Pharmaceutical INC. | $32.11 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $30.89 | 2023 | Prehevbrio |
| Sumitomo Pharma America, INC. | $27.25 | 2025 | Gemtesa |
| Pharmaessentia USA Corporation | $23.94 | 2025 | Besremi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.97 | 2022 | |
| Organon LLC | $22.48 | 2023 | |
| Sanofi Pasteur INC. | $20.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.20 | 2022 | |
| Dexcom, INC. | $18.96 | 2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $18.57 | 2021 | |
| Seqirus USA INC | $15.30 | 2024 | Fluad, Flucelvax |
| Redhill Biopharma INC. | $14.44 | 2020 | |
| Endogastric Solutions, INC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.